Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VGXI, Inc, a provider of DNA plasmids, has announced the execution of a master product sale agreement to supply plasmid between its parent company, VGX International, and BioCancell Therapeutics.
Subscribe to our email newsletter
BioCancell is a biopharmaceuticals corporation specializing in the development of patient-oriented, targeted therapy for the treatment of numerous types of cancer. Products under the agreement will be manufactured at the VGXI, Inc production facility in The Woodlands, Texas.
Avi Barak, CEO of BioCancell Therapeutics, said: “A company developing drugs for various types of cancer relies on its manufacturers for product quality, which is a function of the technologies and advanced services they offer. It is for this reason that we chose to work with VGXI as we move on to plan clinical trials for additional cancer types, requiring the highest manufacturing standards.”